Nothing Special   »   [go: up one dir, main page]

EP0988030A1 - Nanospheres a knob - Google Patents

Nanospheres a knob

Info

Publication number
EP0988030A1
EP0988030A1 EP98926552A EP98926552A EP0988030A1 EP 0988030 A1 EP0988030 A1 EP 0988030A1 EP 98926552 A EP98926552 A EP 98926552A EP 98926552 A EP98926552 A EP 98926552A EP 0988030 A1 EP0988030 A1 EP 0988030A1
Authority
EP
European Patent Office
Prior art keywords
nanoparticle
polypeptide
linking molecule
gene delivery
delivery vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98926552A
Other languages
German (de)
English (en)
Inventor
Hai-Quan Mao
Yan Wang
Barry Byrne
Kam W. Leong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP0988030A1 publication Critical patent/EP0988030A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • This invention is related to improved vehicles for delivering substances to the intracellular milieu.
  • the nanoparticle comprises a polymeric cation and a polyanion, wherein the polyanion consists of nucleic acids, wherein a polypeptide is attached to the surface of said nanoparticle, wherein the polypeptide comprises the knob domain of adenovirus fiber protein.
  • a method of forming solid nanoparticles for delivery to target cells comprises the steps of: forming solid nanoparticles by coacervation of a polyanion consisting of nucleic acids and a polymeric cation; adhering a molecular species to the surface of the nanoparticles wherein the molecular species is selected from the group consisting of a polypeptide comprising the knob domain of adenovirus fiber protein and a linking molecule, wherein if the molecular species is a linking molecule the method further comprises the step of binding a polypeptide comprising the knob domain of adenovirus fiber protein to the linking molecule.
  • a method for introducing genes into cells comprises the steps of: incubating (a) cells to be transfected with (b) solid nanoparticles comprising a coacervate of a polymeric cation and a polyanion consisting of nucleic acids, wherein a polypeptide is attached to said nanoparticles' surface, said polypeptide comprising the knob domain of adenovirus fiber protein.
  • a gene delivery vehicle is provided. A polypeptide is attached to the surface of the gene delivery vehicle. The polypeptide comprises the knob domain of adenovirus fiber protein.
  • FIG. 1 Improvement of transfection efficiency of DNA-chitosan nanospheres into 293 cells with Knob conjugated on the surface of the nanospheres. The DNA encoded luciferase. Luciferase activity is shown.
  • Figure 2. Improvement of transfection efficiency of DNA-chitosan nanospheres into HeLa cells with Knob conjugated on the surface of the nanospheres. The DNA encoded luciferase. Luciferase activity is shown. DETAILED DESCRIPTION
  • Knob domain of the fiber protein of adenovirus can be conjugated to nanospheres or other gene delivery vehicles and that they enhance the uptake of the gene delivery vehicles by cells.
  • the Knob domain functions as a specific ligand to a cell surface component, and that the binding of the ligand to the cell surface component effects internalization of the gene delivery vehicles.
  • Nanospheres are solid particles made by the complex coacervation of a polycation and a polyanion.
  • the polycation can be gelatin, actin, tubulin, cytochromoe C, serum albumin, or histones, or other similar positively charged protein.
  • the polycation can also be a polysaccharide such as chitosan, proteoglycan, methylcellulose, amylose, or starch.
  • the polyanion can be nucleic acids or chondroiton sulfate, for example.
  • Other components such as low molecular weight drugs, proteins, antisense oligonucleotides, and nucleic acids such as plasmid DNAs can also be encapsulated in the nanosphere.
  • Other gene delivery vehicles which may be used include protein-DNA complexes, gold particles, liposomes, and polymeric nanoparticles.
  • Fiber protein is one of the capsid components of human adenovirus. Fiber protein or a portion of fiber protein, in particular the knob domain, can be covalently attached to a nanosphere.
  • fiber protein facilitates the internalization of nanospheres by cells, perhaps by a specific interaction with a receptor protein. This internalization permits more drug or therapeutic agent to reach the intracellular target, thus permitting lower doses to be used than without the fiber protein. This provides both a cost savings and a safety benefit.
  • the surface of nanoparticles or gene delivery vehicles can be easily derivatized for the direct coupling of targeting moieties.
  • carbo- diimides can be used as a derivatizing agent.
  • spacers linking molecules and derivatizing moieties on targeting ligands
  • avidin-biotin can be used to indirectly couple targeting ligands to the nanoparticles.
  • Biotinylated antibodies and/or other biotinylated ligands can be coupled to the avidin-coated nanoparticle surface efficiently because of the high affinity of biotin (I ⁇ lO 15 M "1 ) for avidin (Hazuda, et al. , 1990, Processing of precursor interleukin 1 beta and inflammatory disease, J. Biol. Chem. , 265:6318-22; Wilchek, et al., 1990, Introduction to avidin-biotin technology, Methods In Enzymology, 184:5-13).
  • Orientation-selective attachment of IgGs can be achieved by biotinylating the antibody at the oligosaccharide groups found on the F c portion (O'Shannessy, et al., 1984, A novel procedure for labeling immunoglobulins by conjugation to oligosaccharides moieties, Immunol. Lett. , 8:273-277).
  • This design helps to preserve the total number of available binding sites and renders the attached antibodies less immunogenic to F c receptor-bearing cells such as macrophages.
  • Spacers other than the avidin-biotin bridge can also be used, as are known in the art.
  • Staphylococcal protein A can be coated on the nanoparticles for binding the F c portions of immunoglobulin molecules to the nanoparticles.
  • Cross-linking of linking molecules or targeting ligands to the nanoparticle is used to promote the stability of the nanoparticle as well as to covalently affix the linking molecule or targeting ligand to the nanoparticle.
  • the degree of cross- linking directly affects the rate of nucleic acids release from the microspheres.
  • Cross-linking can be accomplished using glutaraldehyde, carbodiimides such as EDC (l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, DCC (N,N'- dicyclohexylcarbodiimide), carboxyls (peptide bond) linkage, DSS (Disuccinimidyl suberate), SPDP (N-succinimidyl 3-[2-pyridyldithio]propionate bis (sulfosuccinimidyl) suberate), dimethylsuberimidate, etc.
  • EDC l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
  • DCC N,N'- dicyclohexylcarbodiimide
  • carboxyls (peptide bond) linkage DSS (Disuccinimidyl suberate)
  • SPDP N-succinimidyl 3-[2-
  • the nanoparticles of the present invention have good loading properties. Typically, following the method of the present invention, nanoparticles having at least 5% (w/w) nucleic acids can be achieved. Preferably the loading is greater than 10 or 15% nucleic acids. Often nanoparticles of greater than 20 or 30%, but less than 40 or 50% nucleic acids can be achieved. Typically encapsulation efficiencies of nucleic acids into nanoparticles of greater than 95% can be achieved.
  • the method of the present invention involves the coacervation of polymeric cations and nucleic acids. Because this process depends on the interaction of the positively charged polymeric cations and the negatively charged nucleic acids it can be considered as a complex coacervation process. However, sodium sulfate (or ethanol) induces the coacervation reaction by inducing a phase transition, and therefore it could also be considered as a simple coacervation reaction. Nucleic acids are present in the coacervation mixture at a concentration of between 1 ng/ml to 500 g/ml. Desirably the nucleic acids are at least about 2-3 kb in length. Sodium sulfate is present at between 7 and 43 mM.
  • Gelatin or other polymeric cation is present at between about 2 and 7% in the coacervation mixture. Unlike viral vectors, which cannot deliver genes larger than 10 kb, the nanoparticle delivery system of the present invention does not have such size limitations. Nucleic acid molecules of greater than about 2 kb can be used, and nucleic acid molecules even greater than 10 kb may be used. Typically nucleic acids in the range of 2 to 10 kb, 5 to 15 kb, and even 10-50 kb can be encapsulated.
  • the range of possible targets is dependent on the route of injection, e.g., intravenous or intraarterial, subcutaneous, intra-peritoneal, intrathecal, etc.
  • the specificity of this delivery system is affected by the accessibility of the target to blood borne nanoparticles, which in turn, is affected by the size range of the particles. Size of the particles is affected by temperature, component concentration, and pH in the coacervation mixture. The particles can also be size-fractionated, e.g., by sucrose gradient ultracentrifugation. Suitable sizes of nanoparticles are less than 3 ⁇ m, preferably less than 2 ⁇ m, 1 ⁇ m, and even as low as 0.1 ⁇ m.
  • Particles with size less than 150 nanometers can access the interstitial space by traversing through the fenestrations that line most blood vessels walls. Under such circumstances, the range of cells that can be targeted is extensive.
  • An abbreviated list of cells that can be targeted includes the parenchymal cells of the liver sinusoids, the f ⁇ broblasts of the connective tissues, the cells in the Islets of Langerhans in the pancreas, the cardiac myocytes, the Chief and parietal cells of the intestine, osteocytes and chondrocytes in the bone, keratinocytes, nerve cells of the peripheral nervous system, epithelial cells of the kidney and lung, Sertoli cells of the testis, etc.
  • the targetable cell types include erythrocytes, leukocytes (i.e. monocytes, macrophages, B and T lymphocytes, neutrophils, natural killer cells, progenitor cells, mast cells, eosinophils), platelets, and endothelial cells.
  • leukocytes i.e. monocytes, macrophages, B and T lymphocytes
  • neutrophils natural killer cells
  • progenitor cells i.e. monocytes, macrophages, B and T lymphocytes
  • mast cells eosinophils
  • platelets e.g., eothelial cells
  • endothelial cells e.g., endothelial cells.
  • the targetable cells include all cells that resides in the connective tissue (e.g., fibroblasts, mast cells, etc.), Langerhans cells, keratinocytes, and muscle cells.
  • the targetable cells include neurons, glial cells, astrocytes,
  • EXAMPLE 1 Expression and Purification of the Knob Domain of the Adenovirus Type 5 Fiber Protein
  • the knob domain was cloned by PCR amplification using cloned Ad5 plasmid DNA (pJM17, McGrory, et al. , 1988) as the template and specific oligonucleotides designed to facilitate the insertion of the PCR product into the bacterial expression vector pET15b (Novagen).
  • the sequences of the two primers used were CTCGAGGGTGCCATTACAGTAGGAAACAAAAATAATGATAAG (5 1 oligonucleotide) and
  • GGATCCTTATTCTTGGGC AATGTATG AAA AAGTGTAAGAGG 3 ' oligonucleotide, which are partially complementary to specific Ad5 fiber sequences (Chroboczek and Jacrot, 1987).
  • the PCR product of approximately 600 bp was purified by the PCR purification kit (Qiagen), and digested by BamHI and Xhol, then directionally ligated into BamHI-XhoI-digested pET15b.
  • BL21(DE3) cells used as the host strain.
  • a clone containing the appropriate recombinant plasmid was identified by restriction enzyme digestion.
  • the expression of the knob was induced by 0.1 mM IPTG in LB medium and characterized by Western Blot.
  • N-terminus Cells from 100 ml of culture were spun down and resuspended in 18 ml of Native Binding Buffer (20 mM phosphate, 500 mM NaCl, pH 7.8). One ml of 1 % Triton X-100TM was added to achieve good solubilization. The cells were disrupted by sonication in short bursts (20 sec/burst, total 80 seconds), and the cell debris and DNA were precipitated at 10,000 x g for 10 minutes. The pre-equilibrated resin in the column was resuspended with four 5 ml lysate aliquots and gently rocked for 10 minutes to allow for binding of the polyhistidine-containing protein. The resin was then settled by centrifugation, and the supernatant was aspirated. The column was washed three times with 4 ml of Native Binding Buffer, twice with 4 ml Native Wash Buffer (20 mM phosphate,
  • Knob-SH concentration of Knob derivative
  • the mixture was stirred at room temperature for 30 min before 50 mL of 1 M glycine was added to quench the reaction, followed by addition of 250 mg of Knob-SH. After reaction for 60 minutes, the mixture was subjected to ultracentrifugation to harvest the nanospheres.
  • Nanospheres containing 1 mg of DNA were incubated with 1.0-5.0 x 105 cells in each well (pre-plated in 12 well plate) at 37° C and 5% CO 2 in DMEM containing 1% fetal bovine serum (FBS), 2 mM L-glutamine, 50 units/mL penicillin, 50 mg/mL streptomycin, and 10 mg/ mL gentamycin for 4 hours, followed by changing the medium to fresh complete medium (DMEM containing 10% FBS). Cells were cultured for 3 days before assay. Transfection using Lipofectamine (BRL, Gaithersburg, MD, liposome method) was used as control. Luciferase gene expression levels were measured by assaying Luciferase activity in permeabilized cell extracts (Promega, Madison, WI). The light units (LU) were normalized to protein concentration in the cell extracts measured by the BCA method.
  • FBS fetal bovine serum
  • LU light units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne l'isolation et la purification du domaine Knob d'une protéine fibreuse d'adénovirus, ainsi que son utilisation comme ligand pour l'administration intracellulaire d'agents bioactifs, tels que des médicaments, des protéines, des oligonucléotides antisens et des ADN plasmidiques à faible poids moléculaire. La conjugaison de Knob à la surface de nanosphères d'ADN facilite la liaison de nanosphères aux surfaces cellulaires et augmente l'efficacité de transfection de nanosphères d'ADN.
EP98926552A 1997-06-13 1998-06-11 Nanospheres a knob Ceased EP0988030A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4949697P 1997-06-13 1997-06-13
US49496P 1997-06-13
PCT/US1998/012126 WO1998056363A1 (fr) 1997-06-13 1998-06-11 Nanospheres a knob

Publications (1)

Publication Number Publication Date
EP0988030A1 true EP0988030A1 (fr) 2000-03-29

Family

ID=21960134

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98926552A Ceased EP0988030A1 (fr) 1997-06-13 1998-06-11 Nanospheres a knob

Country Status (3)

Country Link
EP (1) EP0988030A1 (fr)
AU (1) AU7836598A (fr)
WO (1) WO1998056363A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
WO2000033886A1 (fr) * 1998-12-04 2000-06-15 Genzyme Corporation Complexes de poudres seches destines a la fourniture de genes
CA2428732C (fr) * 2000-11-15 2018-07-31 Minerva Biotechnologies Corporation Procedes et trousse pour l'analyse simultanee des interactions entre diverses especes chimiques ou biologiques et utilisations associees
AU2002364927A1 (en) * 2001-07-10 2003-06-30 North Carolina State University Nanoparticle delivery vehicle
GB2489714B (en) * 2011-04-05 2013-11-06 Tracesa Ltd Fluid Identification Method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0904100B1 (fr) * 1996-02-09 2006-07-26 Pi-Wan Cheng Administration de molecules actives biologiquement, facilitee par un ligand a un recepteur et un lipide cationique
AU3739697A (en) * 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9856363A1 *

Also Published As

Publication number Publication date
WO1998056363A1 (fr) 1998-12-17
AU7836598A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
US5972707A (en) Gene delivery system
US6025337A (en) Solid microparticles for gene delivery
AU749032B2 (en) Therapeutic nanospheres
US5994316A (en) Method of preparing polynucleotide-carrier complexes for delivery to cells
Guy et al. Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy
Garnett Gene-delivery systems using cationic polymers
US5728399A (en) Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
TWI267380B (en) Nucleic acid-containing complex
JP2004516809A (ja) 選択した化合物を標的に輸送するための分子輸送媒体
Khondee et al. Calcium condensed LABL-TAT complexes effectively target gene delivery to ICAM-1 expressing cells
JP2002537318A (ja) 全身性遺伝子送達のための抗体標的化フラグメントイムノリポソーム
KR20080100376A (ko) 친수성 단백질에 기초한 활성제-농축된 나노입자
JP2003530360A (ja) 薬剤送達のためのペプチド複合体
EP1098632A1 (fr) Inversion de charges de complexes de polyions
WO2000061190A2 (fr) Traitement d'infections intracellulaires
Mok et al. Functional polymers for targeted delivery of nucleic acid drugs
WO1998056363A1 (fr) Nanospheres a knob
JP2002538198A (ja) キャリヤー媒介体及びターゲティング媒介体としての細菌ゴースト
JP2000506388A (ja) 近共通スプライス部位を有する無イントロン遺伝子の発現を増大させるためのウイルスのシス作用性転写後調節配列の用途
US20100113695A1 (en) High capacity non-viral vectors
CA2198361A1 (fr) Administration intracellulaire d'agents chimiques a un type de cellule specifique
CN114081965B (zh) 一种外泌体递送载体及其制备方法、应用
WO1999015687A1 (fr) Complexe polynucleotidique multiconstituant pour transfection cellulaire a haute efficacite

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE JOHNS HOPKINS UNIVERSITY

17Q First examination report despatched

Effective date: 20031027

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20050219